Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Slow release tablet comprising toraesmide active ingredient

The technology of an active ingredient, torasemide, is applied in the field of sustained-release tablets of sulfonylurea pyridine diuretics-torasemide, which can solve the problems of major side effects, achieve small side effects, low production cost, and bioavailability high degree of effect

Inactive Publication Date: 2007-02-28
TIANJIN INSTITUTE OF PHARMA RESEARCH
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The elimination half-life of torasemide in the blood is 2.2 to 5 hours. In order to maintain the trough concentration and still be effective, the dosage must be increased, and long-term medication may bring greater side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Slow release tablet comprising toraesmide active ingredient
  • Slow release tablet comprising toraesmide active ingredient

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0018] Example 1: (common tablet)

[0019] Torsemide 0.5g

[0020] Lactose 8.0g

[0021] Starch 7.0g

[0022] Polyvinylpyrrolidone K30 2.0g

[0023] water qs

[0024] Magnesium stearate qs

[0025] Talc powder qs

[0026] Pass the main drug and auxiliary materials through a 100-mesh sieve respectively, fully mix, then weigh the prescription amount of auxiliary materials and fully mix with the main drug. Add water-based soft materials, granulate with a 20-mesh sieve, dry at 55°C, and sort through a 20-mesh sieve. Finally, add the lubricant and mix evenly for tableting.

example 2

[0030] Torsemide 0.5g

[0031] Lactose 12.0g

[0032] Acrylic resin RS100 3.0g

[0033] Stearic acid 3.0g

[0034] water qs

[0035] Magnesium stearate qs

[0036] Talc powder qs

[0037] Pass the main drug and auxiliary materials through a 100-mesh sieve respectively, fully mix, then weigh the prescription amount of auxiliary materials and fully mix with the main drug. Then add binder to make soft material, granulate with 20-mesh sieve, dry at 55°C, and arrange with 20-mesh sieve. Finally, lubricant or hypromellose is added, mixed evenly and compressed into tablets.

example 3

[0039] The prescription is:

[0040] Torsemide 1.0g

[0041] Lactose 15.0g

[0042] Hypromellose (4000cp) 2.0g

[0043] Ethyl cellulose (100cp) 1.0g

[0044] Sodium Lauryl Sulfate 0.5g

[0045] 2% hypromellose (50% ethanol) qs

[0046] Magnesium stearate qs

[0047] Talc powder qs

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a slow release tablet containing active ingredient of torasemide, which comprises torasemide, slow release material and other auxiliary materials by the weight ratio of 1 : 0.2-20 : 10-200, preferably 1 : 0.5-10 : 20-100. The prepared slow release tablet is suitable for patients of hypertension.

Description

technical field [0001] The invention belongs to the field of drug sustained-release preparations, in particular to a sustained-release tablet of a sulfonylurea pyridine diuretic-torasemide. Background technique [0002] The incidence of cardiovascular disease in my country is high, and the amount of medication accounts for the third largest, among which patients with hypertension account for about 50% of cardiovascular cases. Hypertension is the main risk factor for coronary heart disease. Hypertension cannot be completely cured. Strict control of blood pressure and reduction of heart, brain, kidney, blood vessel and other organ complications are the goals of treatment. The principles of drug treatment of hypertension recently proposed by WHO are as follows: (1) The lowest effective dose of any drug should be used when starting treatment to reduce side effects. (2) Try to apply a 24-hour effective long-acting preparation once a day to achieve round-the-clock treatment. Its...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/44A61K9/22A61P7/10
Inventor 任晓文徐为人李洪起连潇嫣
Owner TIANJIN INSTITUTE OF PHARMA RESEARCH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com